Kenvue (NYSE:KVUE) Posts Earnings Results, Meets Expectations

Kenvue (NYSE:KVUE) issued its quarterly earnings data on Thursday. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26, Zacks reports. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. Kenvue updated its FY 2025 guidance to 1.440-1.469 EPS.

Kenvue Trading Down 4.6 %

Shares of Kenvue stock traded down $0.96 during trading on Thursday, reaching $19.78. 25,806,069 shares of the stock were exchanged, compared to its average volume of 12,576,146. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock’s fifty day moving average is $21.70 and its 200 day moving average is $21.95. The firm has a market cap of $37.93 billion, a price-to-earnings ratio of 35.97, a price-to-earnings-growth ratio of 2.05 and a beta of 1.45. Kenvue has a 1 year low of $17.67 and a 1 year high of $24.46.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 4.15%. Kenvue’s dividend payout ratio is currently 149.09%.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and reduced their target price for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a research note on Monday. Barclays reduced their target price on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. Bank of America raised their price objective on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Finally, Citigroup reduced their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $23.08.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.